Together, the results from this study have identified for the first time that honokiol inhibits the migration of NSCLC cells and that this effect involves: (i) the inhibitory effect of honokiol on COX-2 and PGE2, (ii) the inhibitory effect of honokiol on NF-κB activation, and (iii) inactivation of β-catenin signaling. The gene discussed is PTGS2; the disease is non-small cell lung carcinoma.